Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non-Hodgkin Lymphoma-Pipeline Review, H1 2015

Non-Hodgkin Lymphoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Non-Hodgkin Lymphoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Non-Hodgkin Lymphoma-Pipeline Review, H1 2015', provides an overview of the Non-Hodgkin Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Non-Hodgkin Lymphoma Overview 8

Therapeutics Development 9

Non-Hodgkin Lymphoma-Therapeutics under Development by Companies 11

Non-Hodgkin Lymphoma-Therapeutics under Investigation by Universities/Institutes 21

Non-Hodgkin Lymphoma-Pipeline Products Glance 23

Non-Hodgkin Lymphoma-Products under Development by Companies 27

Non-Hodgkin Lymphoma-Products under Investigation by Universities/Institutes 43

Non-Hodgkin Lymphoma-Companies Involved in Therapeutics Development 45

Non-Hodgkin Lymphoma-Therapeutics Assessment 161

Drug Profiles 189

Non-Hodgkin Lymphoma-Recent Pipeline Updates 560

Non-Hodgkin Lymphoma-Dormant Projects 813

Non-Hodgkin Lymphoma-Discontinued Products 826

Non-Hodgkin Lymphoma-Product Development Milestones 831

Appendix 844

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2015 32

Number of Products under Development for Non-Hodgkin Lymphoma-Comparative Analysis, H1 2015 33

Number of Products under Development by Companies, H1 2015 35

Number of Products under Development by Companies, H1 2015 (Contd..1) 36

Number of Products under Development by Companies, H1 2015 (Contd..2) 37

Number of Products under Development by Companies, H1 2015 (Contd..3) 38

Number of Products under Development by Companies, H1 2015 (Contd..4) 39

Number of Products under Development by Companies, H1 2015 (Contd..5) 40

Number of Products under Development by Companies, H1 2015 (Contd..6) 41

Number of Products under Development by Companies, H1 2015 (Contd..7) 42

Number of Products under Development by Companies, H1 2015 (Contd..8) 43

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Development, H1 2015 48

Comparative Analysis by Unknown Stage Development, H1 2015 49

Products under Development by Companies, H1 2015 50

Products under Development by Companies, H1 2015 (Contd..1) 51

Products under Development by Companies, H1 2015 (Contd..2) 52

Products under Development by Companies, H1 2015 (Contd..3) 53

Products under Development by Companies, H1 2015 (Contd..4) 54

Products under Development by Companies, H1 2015 (Contd..5) 55

Products under Development by Companies, H1 2015 (Contd..6) 56

Products under Development by Companies, H1 2015 (Contd..7) 57

Products under Development by Companies, H1 2015 (Contd..8) 58

Products under Development by Companies, H1 2015 (Contd..9) 59

Products under Development by Companies, H1 2015 (Contd..10) 60

Products under Development by Companies, H1 2015 (Contd..11) 61

Products under Development by Companies, H1 2015 (Contd..12) 62

Products under Development by Companies, H1 2015 (Contd..13) 63

Products under Development by Companies, H1 2015 (Contd..14) 64

Products under Development by Companies, H1 2015 (Contd..15) 65

Products under Investigation by Universities/Institutes, H1 2015 66

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 67

Non-Hodgkin Lymphoma-Pipeline by AB Science, H1 2015 68

Non-Hodgkin Lymphoma-Pipeline by AbbVie Inc., H1 2015 69

Non-Hodgkin Lymphoma-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 70

Non-Hodgkin Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 71

Non-Hodgkin Lymphoma-Pipeline by ADC Therapeutics Sarl, H1 2015 72

Non-Hodgkin Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 73

Non-Hodgkin Lymphoma-Pipeline by Agilvax, Inc., H1 2015 74

Non-Hodgkin Lymphoma-Pipeline by Akron Molecules AG, H1 2015 75

Non-Hodgkin Lymphoma-Pipeline by Allinky Biopharma, H1 2015 76

Non-Hodgkin Lymphoma-Pipeline by Amgen Inc., H1 2015 77

Non-Hodgkin Lymphoma-Pipeline by Aptose Biosciences Inc., H1 2015 78

Non-Hodgkin Lymphoma-Pipeline by arGEN-X BV, H1 2015 79

Non-Hodgkin Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 80

Non-Hodgkin Lymphoma-Pipeline by AstraZeneca Plc, H1 2015 81

Non-Hodgkin Lymphoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 82

Non-Hodgkin Lymphoma-Pipeline by Bayer AG, H1 2015 83

Non-Hodgkin Lymphoma-Pipeline by BioAtla, LLC, H1 2015 84

Non-Hodgkin Lymphoma-Pipeline by Biogenomics Limited, H1 2015 85

Non-Hodgkin Lymphoma-Pipeline by BioInvent International AB, H1 2015 86

Non-Hodgkin Lymphoma-Pipeline by BioMedics Japan Inc., H1 2015 87

Non-Hodgkin Lymphoma-Pipeline by Biothera, Inc., H1 2015 88

Non-Hodgkin Lymphoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 89

Non-Hodgkin Lymphoma-Pipeline by Boston Biomedical, Inc., H1 2015 90

Non-Hodgkin Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 91

Non-Hodgkin Lymphoma-Pipeline by Calimmune, Inc., H1 2015 92

Non-Hodgkin Lymphoma-Pipeline by Calithera Biosciences, Inc., H1 2015 93

Non-Hodgkin Lymphoma-Pipeline by Celgene Corporation, H1 2015 94

Non-Hodgkin Lymphoma-Pipeline by Cell Medica Limited, H1 2015 95

Non-Hodgkin Lymphoma-Pipeline by Celltrion, Inc., H1 2015 96

Non-Hodgkin Lymphoma-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 97

Non-Hodgkin Lymphoma-Pipeline by Celon Pharma Sp. z o.o., H1 2015 98

Non-Hodgkin Lymphoma-Pipeline by Chipscreen Biosciences Ltd, H1 2015 99

Non-Hodgkin Lymphoma-Pipeline by Coherus BioSciences, Inc., H1 2015 100

Non-Hodgkin Lymphoma-Pipeline by Conkwest, Inc., H1 2015 101

Non-Hodgkin Lymphoma-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 102

Non-Hodgkin Lymphoma-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 103

Non-Hodgkin Lymphoma-Pipeline by Curis, Inc., H1 2015 104

Non-Hodgkin Lymphoma-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 105

Non-Hodgkin Lymphoma-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 106

Non-Hodgkin Lymphoma-Pipeline by Dynavax Technologies Corporation, H1 2015 107

Non-Hodgkin Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 108

Non-Hodgkin Lymphoma-Pipeline by Eli Lilly and Company, H1 2015 109

Non-Hodgkin Lymphoma-Pipeline by Emergent BioSolutions Inc., H1 2015 110

Non-Hodgkin Lymphoma-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 111

Non-Hodgkin Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 112

Non-Hodgkin Lymphoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 113

Non-Hodgkin Lymphoma-Pipeline by Formula Pharmaceuticals, Inc., H1 2015 114

Non-Hodgkin Lymphoma-Pipeline by Galderma S.A., H1 2015 115

Non-Hodgkin Lymphoma-Pipeline by Gamida Cell Ltd., H1 2015 116

Non-Hodgkin Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 117

Non-Hodgkin Lymphoma-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 118

Non-Hodgkin Lymphoma-Pipeline by Hetero Drugs Limited, H1 2015 119

Non-Hodgkin Lymphoma-Pipeline by Hospira, Inc., H1 2015 120

Non-Hodgkin Lymphoma-Pipeline by iDD biotech SAS, H1 2015 121

Non-Hodgkin Lymphoma-Pipeline by Immune Design Corp., H1 2015 122

Non-Hodgkin Lymphoma-Pipeline by Immunomedics, Inc., H1 2015 123

Non-Hodgkin Lymphoma-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 124

Non-Hodgkin Lymphoma-Pipeline by Incyte Corporation, H1 2015 125

Non-Hodgkin Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 126

Non-Hodgkin Lymphoma-Pipeline by Innate Pharma SA, H1 2015 127

Non-Hodgkin Lymphoma-Pipeline by Innovent Biologics, Inc., H1 2015 128

Non-Hodgkin Lymphoma-Pipeline by Johnson & Johnson, H1 2015 129

Non-Hodgkin Lymphoma-Pipeline by Juno Therapeutics Inc., H1 2015 130

Non-Hodgkin Lymphoma-Pipeline by Kainos Medicine, Inc., H1 2015 131

Non-Hodgkin Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 132

Non-Hodgkin Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 133

Non-Hodgkin Lymphoma-Pipeline by Komipharm International Co., Ltd., H1 2015 134

Non-Hodgkin Lymphoma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 135

Non-Hodgkin Lymphoma-Pipeline by MedImmune, LLC, H1 2015 136

Non-Hodgkin Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 137

Non-Hodgkin Lymphoma-Pipeline by Merck KGaA, H1 2015 138

Non-Hodgkin Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 139

Non-Hodgkin Lymphoma-Pipeline by Mirna Therapeutics, Inc., H1 2015 140

Non-Hodgkin Lymphoma-Pipeline by Mission Therapeutics Ltd, H1 2015 141

Non-Hodgkin Lymphoma-Pipeline by MorphoSys AG, H1 2015 142

Non-Hodgkin Lymphoma-Pipeline by Mundipharma International Ltd, H1 2015 143

Non-Hodgkin Lymphoma-Pipeline by Neopharm Ltd., H1 2015 144

Non-Hodgkin Lymphoma-Pipeline by Neumedicines Inc., H1 2015 145

Non-Hodgkin Lymphoma-Pipeline by Nordic Nanovector ASA, H1 2015 146

Non-Hodgkin Lymphoma-Pipeline by Novartis AG, H1 2015 147

Non-Hodgkin Lymphoma-Pipeline by NuCana BioMed Limited, H1 2015 148

Non-Hodgkin Lymphoma-Pipeline by Oncobiologics, Inc., H1 2015 149

Non-Hodgkin Lymphoma-Pipeline by OncoSec Medical Inc., H1 2015 150

Non-Hodgkin Lymphoma-Pipeline by Onxeo SA, H1 2015 151

Non-Hodgkin Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 152

Non-Hodgkin Lymphoma-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 153

Non-Hodgkin Lymphoma-Pipeline by Oxford BioTherapeutics Ltd, H1 2015 154

Non-Hodgkin Lymphoma-Pipeline by Panacea Biotec Limited, H1 2015 155

Non-Hodgkin Lymphoma-Pipeline by Pfizer Inc., H1 2015 156

Non-Hodgkin Lymphoma-Pipeline by Pharma Mar, S.A., H1 2015 157

Non-Hodgkin Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 158

Non-Hodgkin Lymphoma-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 159

Non-Hodgkin Lymphoma-Pipeline by ProNAi Therapeutics, Inc., H1 2015 160

Non-Hodgkin Lymphoma-Pipeline by Richter Gedeon Nyrt., H1 2015 161

Non-Hodgkin Lymphoma-Pipeline by Sanofi, H1 2015 162

Non-Hodgkin Lymphoma-Pipeline by Sareum Holdings Plc, H1 2015 163

Non-Hodgkin Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 164

Non-Hodgkin Lymphoma-Pipeline by Senhwa Biosciences, Inc., H1 2015 165

Non-Hodgkin Lymphoma-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 166

Non-Hodgkin Lymphoma-Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2015 167

Non-Hodgkin Lymphoma-Pipeline by Solasia Pharma K.K., H1 2015 168

Non-Hodgkin Lymphoma-Pipeline by Soligenix, Inc., H1 2015 169

Non-Hodgkin Lymphoma-Pipeline by Sorrento Therapeutics, Inc., H1 2015 170

Non-Hodgkin Lymphoma-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 171

Non-Hodgkin Lymphoma-Pipeline by Stemline Therapeutics, Inc., H1 2015 172

Non-Hodgkin Lymphoma-Pipeline by Supratek Pharma Inc., H1 2015 173

Non-Hodgkin Lymphoma-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 174

Non-Hodgkin Lymphoma-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 175

Non-Hodgkin Lymphoma-Pipeline by TetraLogic Pharmaceuticals, H1 2015 176

Non-Hodgkin Lymphoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 177

Non-Hodgkin Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 178

Non-Hodgkin Lymphoma-Pipeline by Theravectys S.A., H1 2015 179

Non-Hodgkin Lymphoma-Pipeline by Transgene Biotek Limited, H1 2015 180

Non-Hodgkin Lymphoma-Pipeline by Vivia Biotech, S.L., H1 2015 181

Non-Hodgkin Lymphoma-Pipeline by Xenetic Biosciences plc, H1 2015 182

Non-Hodgkin Lymphoma-Pipeline by Zymeworks Inc., H1 2015 183

Assessment by Monotherapy Products, H1 2015 184

Assessment by Combination Products, H1 2015 185

Number of Products by Stage and Target, H1 2015 187

Number of Products by Stage and Mechanism of Action, H1 2015 199

Number of Products by Stage and Route of Administration, H1 2015 209

Number of Products by Stage and Molecule Type, H1 2015 211

Non-Hodgkin Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 583

Non-Hodgkin Lymphoma-Dormant Projects, H1 2015 836

Non-Hodgkin Lymphoma-Dormant Projects (Contd..1), H1 2015 837

Non-Hodgkin Lymphoma-Dormant Projects (Contd..2), H1 2015 838

Non-Hodgkin Lymphoma-Dormant Projects (Contd..3), H1 2015 839

Non-Hodgkin Lymphoma-Dormant Projects (Contd..4), H1 2015 840

Non-Hodgkin Lymphoma-Dormant Projects (Contd..5), H1 2015 841

Non-Hodgkin Lymphoma-Dormant Projects (Contd..6), H1 2015 842

Non-Hodgkin Lymphoma-Dormant Projects (Contd..7), H1 2015 843

Non-Hodgkin Lymphoma-Dormant Projects (Contd..8), H1 2015 844

Non-Hodgkin Lymphoma-Dormant Projects (Contd..9), H1 2015 845

Non-Hodgkin Lymphoma-Dormant Projects (Contd..10), H1 2015 846

Non-Hodgkin Lymphoma-Dormant Projects (Contd..11), H1 2015 847

Non-Hodgkin Lymphoma-Dormant Projects (Contd..12), H1 2015 848

Non-Hodgkin Lymphoma-Discontinued Products, H1 2015 849

Non-Hodgkin Lymphoma-Discontinued Products (Contd..1), H1 2015 850

Non-Hodgkin Lymphoma-Discontinued Products (Contd..2), H1 2015 851

Non-Hodgkin Lymphoma-Discontinued Products (Contd..3), H1 2015 852

Non-Hodgkin Lymphoma-Discontinued Products (Contd..4), H1 2015 853

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2015 32

Number of Products under Development for Non-Hodgkin Lymphoma-Comparative Analysis, H1 2015 33

Number of Products under Development by Companies, H1 2015 34

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Products, H1 2015 48

Assessment by Monotherapy Products, H1 2015 184

Assessment by Combination Products, H1 2015 185

Number of Products by Top 10 Targets, H1 2015 186

Number of Products by Stage and Top 10 Targets, H1 2015 186

Number of Products by Top 10 Mechanism of Actions, H1 2015 198

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 198

Number of Products by Top 10 Routes of Administration, H1 2015 208

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 208

Number of Products by Top 10 Molecule Types, H1 2015 210

Number of Products by Stage and Top 10 Molecule Types, H1 2015 210

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ADC Therapeutics Sarl

Affimed Therapeutics AG

Agilvax, Inc.

Akron Molecules AG

Allinky Biopharma

Amgen Inc.

Aptose Biosciences Inc.

arGEN-X BV

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BioAtla, LLC

Biogenomics Limited

BioInvent International AB

BioMedics Japan Inc.

Biothera, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calimmune, Inc.

Calithera Biosciences, Inc.

Celgene Corporation

Cell Medica Limited

Celltrion, Inc.

Cellular Biomedicine Group, Inc.

Celon Pharma Sp. z o.o.

Chipscreen Biosciences Ltd

Coherus BioSciences, Inc.

Conkwest, Inc.

Constellation Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc.

Curis, Inc.

Cyclacel Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc.

Dynavax Technologies Corporation

Eisai Co., Ltd.

Eli Lilly and Company

Emergent BioSolutions Inc.

Epirus Biopharmaceuticals, Inc.

EpiZyme, Inc.

F. Hoffmann-La Roche Ltd.

Formula Pharmaceuticals, Inc.

Galderma S.A.

Gamida Cell Ltd.

Gilead Sciences, Inc.

Grupo Ferrer Internacional, S.A.

Hetero Drugs Limited

Hospira, Inc.

iDD biotech SAS

Immune Design Corp.

Immunomedics, Inc.

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Innate Pharma SA

Innovent Biologics, Inc.

Johnson & Johnson

Juno Therapeutics Inc.

Kainos Medicine, Inc.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

Komipharm International Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

Mission Therapeutics Ltd

MorphoSys AG

Mundipharma International Ltd

Neopharm Ltd.

Neumedicines Inc.

Nordic Nanovector ASA

Novartis AG

NuCana BioMed Limited

Oncobiologics, Inc.

OncoSec Medical Inc.

Onxeo SA

Onyx Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

Panacea Biotec Limited

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Polaris Pharmaceuticals, Inc.

ProNAi Therapeutics, Inc.

Richter Gedeon Nyrt.

Sanofi

Sareum Holdings Plc

Seattle Genetics, Inc.

Senhwa Biosciences, Inc.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shanghai Henlius Biotech Co., Ltd.

Solasia Pharma K.K.

Soligenix, Inc.

Sorrento Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Supratek Pharma Inc.

Taiwan Liposome Company, Ltd.

Tekmira Pharmaceuticals Corp.

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

TG Therapeutics, Inc.

Theravectys S.A.

Transgene Biotek Limited

Vivia Biotech, S.L.

Xenetic Biosciences plc

Zymeworks Inc.

Non-Hodgkin Lymphoma Therapeutic Products under Development, Key Players in Non-Hodgkin Lymphoma Therapeutics, Non-Hodgkin Lymphoma Pipeline Overview, Non-Hodgkin Lymphoma Pipeline, Non-Hodgkin Lymphoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com